Shares of Mesoblast Ltd. (MESO) are rising above 25% in pre-market today, after the company announced that it plans to evaluate its allogeneic mesenchymal stem cell or MSC product candidate remestemcel-L in patients with acute respiratory distress syndrome or ARDS caused by coronavirus (COVID-19) in the United States, Australia, China and Europe.
from RTT - Before the Bell https://ift.tt/39HlBG7
via IFTTT
No comments:
Post a Comment